Private equity-backed royalty deals, a relatively new edition to the biotech world, have already evolved from financing vehicle to strategic portfolio management tool. Now they seem to be evolving again, this time toward earlier-stage project financing, and they're starting to look a little like one of the oldest tricks in biotech's playbook: the Research and Development Limited Partnership (R&DLP). (BioWorld Today)
Arena Pharmaceuticals Inc. released data from its Phase III BLOOM-DM trial of weight loss drug lorcaserin in obese and overweight diabetics on Tuesday, sparking plenty of debate among analysts and investors about whether the new findings would help – or hurt – the company's chances at addressing issues raised in an FDA complete response letter last month. (BioWorld Today)
Private equity-backed royalty deals, a relatively new edition to the biotech world, have already evolved from financing vehicle to strategic portfolio management tool. Now they seem to be evolving again, this time toward earlier-stage project financing, and they're starting to look a little like one of the oldest tricks in biotech's playbook: the Research and Development Limited Partnership (R&DLP).
